PL2948777T3 - Białka z powtórzeniami dipeptydowymi jako cel terapeutyczny w chorobach neurodegeneracyjnych z ekspansją powtórzeń heksanukleotydowych - Google Patents
Białka z powtórzeniami dipeptydowymi jako cel terapeutyczny w chorobach neurodegeneracyjnych z ekspansją powtórzeń heksanukleotydowychInfo
- Publication number
- PL2948777T3 PL2948777T3 PL14701089T PL14701089T PL2948777T3 PL 2948777 T3 PL2948777 T3 PL 2948777T3 PL 14701089 T PL14701089 T PL 14701089T PL 14701089 T PL14701089 T PL 14701089T PL 2948777 T3 PL2948777 T3 PL 2948777T3
- Authority
- PL
- Poland
- Prior art keywords
- repeat
- dipeptide
- neurodegenerative diseases
- therapeutic target
- hexanucleotide
- Prior art date
Links
- 230000004770 neurodegeneration Effects 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2013/000190 WO2014114303A1 (fr) | 2013-01-22 | 2013-01-22 | Protéines à répétitions de dipeptides comme cible thérapeutique dans des maladies neurodégénératives avec expansion de répétitions hexanucléotidiques |
| EP13185419 | 2013-09-20 | ||
| PCT/EP2014/051204 WO2014114660A1 (fr) | 2013-01-22 | 2014-01-22 | Protéines à répétition dipeptidique en tant que cible thérapeutique dans des maladies neurodégénératives ayant une expansion de répétition hexanucléotidique |
| EP14701089.6A EP2948777B1 (fr) | 2013-01-22 | 2014-01-22 | Protéines à répétition dipeptidique en tant que cible thérapeutique dans des maladies neurodégénératives ayant une expansion de répétition hexanucléotidique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2948777T3 true PL2948777T3 (pl) | 2019-12-31 |
Family
ID=49999965
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14701089T PL2948777T3 (pl) | 2013-01-22 | 2014-01-22 | Białka z powtórzeniami dipeptydowymi jako cel terapeutyczny w chorobach neurodegeneracyjnych z ekspansją powtórzeń heksanukleotydowych |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10066007B2 (fr) |
| EP (2) | EP3588091A1 (fr) |
| CY (1) | CY1122079T1 (fr) |
| DK (1) | DK2948777T3 (fr) |
| ES (1) | ES2744804T3 (fr) |
| HR (1) | HRP20191608T1 (fr) |
| HU (1) | HUE046434T2 (fr) |
| LT (1) | LT2948777T (fr) |
| PL (1) | PL2948777T3 (fr) |
| PT (1) | PT2948777T (fr) |
| RS (1) | RS59283B1 (fr) |
| SI (1) | SI2948777T1 (fr) |
| SM (1) | SMT201900507T1 (fr) |
| WO (1) | WO2014114660A1 (fr) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2888486A1 (fr) | 2012-10-15 | 2014-04-24 | Isis Pharmaceuticals, Inc. | Compositions permettant de moduler l'expression de c90rf72 |
| ES2762326T5 (es) | 2012-10-15 | 2023-04-27 | Ionis Pharmaceuticals Inc | Métodos para modular la expresión de C9ORF72 |
| WO2014062736A1 (fr) | 2012-10-15 | 2014-04-24 | Isis Pharmaceuticals, Inc. | Procédés permettant de surveiller l'expression de c9orf72 |
| US10066007B2 (en) * | 2013-01-22 | 2018-09-04 | Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) | Dipeptide-repeat proteins as therapeutic target in neurodegenerative diseases with hexanucleotide repeat expansion |
| EP2948471A4 (fr) | 2013-01-24 | 2016-08-10 | Mayo Foundation | Procédés et matériaux de détection d'une dégénérescence du lobe frontotemporal positive aux expansions de répétitions hexanucléotidiques du gène c9orf72 ou d'une sclérose latérale amyotrophique positive aux expansions de répétitions hexanucléotidiques du gène c9orf72 |
| HK1220227A1 (zh) | 2013-03-14 | 2017-04-28 | University Of Florida Research Foundation, Inc. | 与als有关的重复含有蛋白质的二氨基酸 |
| RU2748426C2 (ru) | 2013-10-11 | 2021-05-25 | Ионис Фармасьютикалз, Инк. | Композиции для модуляции экспрессии c90rf72 |
| BR112017006598A2 (pt) * | 2014-09-30 | 2018-04-17 | Neurimmune Holding Ag | anticorpo de repetições antidipeptídeo derivado de ser humano (dprs) |
| SMT202000165T1 (it) * | 2015-04-16 | 2020-05-08 | Ionis Pharmaceuticals Inc | Composizioni per modulare l'espressione di c9orf72 |
| WO2016196324A1 (fr) | 2015-05-29 | 2016-12-08 | University Of Floridia Research Foundation, Inc. | Méthodes de diagnostic de la maladie de huntington |
| US11260073B2 (en) | 2015-11-02 | 2022-03-01 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating C90RF72 |
| CA3019847A1 (fr) | 2016-04-04 | 2017-10-12 | University Of Florida Research Foundation, Incorporated | Manipulation d'eif3 pour moduler une traduction non-atg associee a une repetition (ran) |
| AU2018255293B2 (en) | 2017-04-17 | 2024-03-07 | University Of Florida Research Foundation, Incorporated | Regulation of RAN translation by PKR and eIF2a-P pathways |
| JP6959632B2 (ja) * | 2017-05-15 | 2021-11-02 | 学校法人近畿大学 | 筋萎縮性側索硬化症又は前頭側頭型認知症の予防又は治療剤 |
| WO2019067587A1 (fr) | 2017-09-26 | 2019-04-04 | University Of Florida Research Foundation, Incorporated | Utilisation de metformine et d'analogues de celle-ci pour réduire les taux de protéine ran lors d'un traitement de troubles neurologiques |
| MA52712A (fr) | 2018-04-27 | 2021-03-31 | Biogen Ma Inc | Anticorps anti-(poly-ga) dirigé contre des répétitions dipeptidiques (dpr) d'origine humaine |
| CN108795935B (zh) * | 2018-05-23 | 2022-06-21 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | 日本血吸虫SjELAV-like 1基因的siRNA及其应用 |
| JP7505788B2 (ja) * | 2018-10-01 | 2024-06-25 | ユナイテッド ニューロサイエンス | Ｃ９ｏｒｆ７２に由来するジペプチドリピートタンパク質に対して指向化されたペプチド免疫原コンストラクト |
| US20220202935A1 (en) * | 2019-05-02 | 2022-06-30 | Deutsches Zentrum Für Neurodegenrative Erkrankungen E.V.(Dzne) | Immunogen for Preventing or Treating Familial Frontotemporal Dementia (FTD) and/or Amyotrophic Lateral Sclerosis (ALS) |
| AU2020310843A1 (en) * | 2019-07-05 | 2022-01-20 | University Of Florida Research Foundation, Incorporated | Methods for treating RAN protein-associated neurological diseases |
| AU2020348916A1 (en) * | 2019-09-20 | 2022-04-07 | University Of Florida Research Foundation, Incorporated | Detection of antibodies against RAN proteins from serum and tissue lysates |
| AU2020354387A1 (en) * | 2019-09-23 | 2022-04-07 | University Of Florida Research Foundation, Incorporated | Vaccine therapy for ran protein diseases |
| WO2023244542A1 (fr) * | 2022-06-13 | 2023-12-21 | Yeefan Med Inc | Procédés de détection de précipités de b-isox ou de protéines capturées en tant que biomarqueurs de biofluide |
| AU2023373378A1 (en) * | 2022-11-01 | 2025-04-24 | University Of Florida Research Foundation, Incorporated | Interrupted ran proteins in disease |
| EP4615415A1 (fr) * | 2022-11-11 | 2025-09-17 | Mayo Foundation for Medical Education and Research | Traitement de protéinopathies |
| WO2024229355A1 (fr) * | 2023-05-04 | 2024-11-07 | The Johns Hopkins University | Méthodes de diminution de la mort, de l'inflammation et de la dégénérescence neuronales |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030143668A1 (en) * | 2001-06-18 | 2003-07-31 | National Institute Of Advanced Industrial | Guanosine triphosphate-binding protein coupled receptors |
| US20040102608A1 (en) * | 2002-05-13 | 2004-05-27 | Cornell Research Foundation, Inc. | Multiblock copolymers having improved mechanical properties |
| WO2005103235A1 (fr) | 2004-04-19 | 2005-11-03 | Denka Seiken Co., Ltd. | Méthode de production de virus |
| EP1997877B1 (fr) * | 2006-03-17 | 2014-03-05 | Sanyo Chemical Industries, Ltd. | Substrat de culture de cellules |
| CA2757354A1 (fr) | 2009-04-02 | 2010-10-07 | Laura P.W. Ranum | Polypeptides associes a des expansions de repetitions nucleotidiques et leurs utilisations |
| CA2794614C (fr) * | 2010-05-21 | 2020-12-15 | Xl-Protein Gmbh | Polypeptides biosynthetiques en pelote statistique de proline/alanine et leurs utilisations |
| CA2888486A1 (fr) * | 2012-10-15 | 2014-04-24 | Isis Pharmaceuticals, Inc. | Compositions permettant de moduler l'expression de c90rf72 |
| US10066007B2 (en) * | 2013-01-22 | 2018-09-04 | Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) | Dipeptide-repeat proteins as therapeutic target in neurodegenerative diseases with hexanucleotide repeat expansion |
-
2014
- 2014-01-22 US US14/762,623 patent/US10066007B2/en active Active
- 2014-01-22 HR HRP20191608 patent/HRP20191608T1/hr unknown
- 2014-01-22 EP EP19180100.0A patent/EP3588091A1/fr active Pending
- 2014-01-22 SM SM20190507T patent/SMT201900507T1/it unknown
- 2014-01-22 RS RSP20191145 patent/RS59283B1/sr unknown
- 2014-01-22 HU HUE14701089A patent/HUE046434T2/hu unknown
- 2014-01-22 EP EP14701089.6A patent/EP2948777B1/fr active Active
- 2014-01-22 WO PCT/EP2014/051204 patent/WO2014114660A1/fr not_active Ceased
- 2014-01-22 SI SI201431324T patent/SI2948777T1/sl unknown
- 2014-01-22 ES ES14701089T patent/ES2744804T3/es active Active
- 2014-01-22 PL PL14701089T patent/PL2948777T3/pl unknown
- 2014-01-22 DK DK14701089.6T patent/DK2948777T3/da active
- 2014-01-22 PT PT14701089T patent/PT2948777T/pt unknown
- 2014-01-22 LT LTEP14701089.6T patent/LT2948777T/lt unknown
-
2019
- 2019-09-05 CY CY20191100935T patent/CY1122079T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI2948777T1 (sl) | 2019-11-29 |
| CY1122079T1 (el) | 2020-11-25 |
| US10066007B2 (en) | 2018-09-04 |
| ES2744804T3 (es) | 2020-02-26 |
| RS59283B1 (sr) | 2019-10-31 |
| EP2948777B1 (fr) | 2019-06-26 |
| DK2948777T3 (da) | 2019-09-23 |
| LT2948777T (lt) | 2019-09-25 |
| EP2948777A1 (fr) | 2015-12-02 |
| US20150361166A1 (en) | 2015-12-17 |
| SMT201900507T1 (it) | 2019-11-13 |
| HRP20191608T1 (hr) | 2019-12-13 |
| EP3588091A1 (fr) | 2020-01-01 |
| PT2948777T (pt) | 2019-09-26 |
| WO2014114660A1 (fr) | 2014-07-31 |
| HUE046434T2 (hu) | 2020-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2948777T1 (sl) | Dipeptidno ponavljajoči se proteini kot terapevtski cilj pri nevrodegenerativnih boleznih s ponavljajočo ekspanzijo heksanukleotida | |
| IL245744A0 (en) | Therapeutic peptides | |
| LT3041864T (lt) | Il-18 surišantis baltymas (il-18p) uždegiminių ligų atvejais | |
| SG10201709131UA (en) | Continuous purification of therapeutic proteins | |
| SG11201506766PA (en) | Therapeutic peptides | |
| SG11201508469YA (en) | Therapeutic peptides | |
| ZA201600086B (en) | Therapeutic fusion protein | |
| SG11201509012QA (en) | Sobetirome in the treatment of myelination diseases | |
| SG11201505198WA (en) | Protein purification methods | |
| SG11201603028SA (en) | Purification of proteins | |
| SG11201505204VA (en) | Protein purification process | |
| GB2523882B (en) | Hint based spot healing techniques | |
| GB201308057D0 (en) | Protein | |
| GB201304973D0 (en) | Recombinant protein | |
| IL240639A0 (en) | Formulations and methods for increased recombinant production of protein | |
| SG11201509450QA (en) | Methods to produce particles comprising therapeutic proteins | |
| GB201401955D0 (en) | Protein | |
| EP2978770A4 (fr) | Repliement de protéines | |
| GB201309967D0 (en) | Therapeutic combinations | |
| GB201320209D0 (en) | Improvements in or relating to protein Micro-nets | |
| GB201804143D0 (en) | Human target II | |
| GB201302030D0 (en) | Protein | |
| GB201302031D0 (en) | Protein | |
| GB201301072D0 (en) | Therapeutic Moisturiser | |
| GB201300778D0 (en) | Therapeutic moisturiser |